Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any chronic illness must be documented to be in stable condition~* Male, or a female agrees to remain abstinent, or use, or have their partner use, 2 acceptable methods of contraception through 6 weeks after receiving study vaccination; or a female who is not of reproductive potential~Exclusion Criteria:~* Is or has an immediate family member who is investigational site or sponsor staff directly involved with this trial~* Prior administration of any pneumococcal vaccine~* History of invasive pneumococcal disease~* Known hypersensitivity to any component of the pneumococcal polysaccharide vaccine, of the pneumococcal conjugate vaccine, or any diphtheria toxoid-containing vaccine~* Known or suspected impairment of immunological function, documented Human Immunodeficiency Virus (HIV) infection, asplenia, or history of autoimmune disease~* Received systemic corticosteroids (equivalent of \>=2 mg/kg total daily dose of prednisone or \>=20 mg/kg for persons weighing \>10 kg) for \>=14 consecutive days and has not completed treatment \<=30 days before study vaccination, or has received systemic corticosteroids exceeding physiological doses (\~5 mg/day prednisone equivalent) within 14 days before study vaccination (topical, ophthalmic, intra-articular, and inhaled/nebulized steroids are permitted).~* Has a coagulation disorder contraindicating intramuscular vaccination~* Receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and treatments associated with organ or bone marrow transplantation or autoimmune disease~* Received a blood transfusion or blood products, including immunoglobulins \<=6 months before receiving study vaccine, or is scheduled to receive them within 30 days~* Participated in another clinical study of an investigational product \<=2 months before or during the current study~* Is breast-feeding

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo (Type: EXPERIMENTAL): Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Pneumovax™ 23 0.5 mL intramuscular injection at Week 8, and Placebo 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.
- Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 (Type: PLACEBO_COMPARATOR): Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Placebo 0.5 mL intramuscular injection at Week 8, and Pneumovax™ 23 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.

Based on this trial design, predict the completion outcome and termination type (if applicable).